Recurrent Prostate Cancer Clinical Trials

11 recruiting

Recurrent Prostate Cancer Trials at a Glance

15 actively recruiting trials for recurrent prostate cancer are listed on ClinicalTrialsFinder across 6 cities in 8 countries. The largest study group is Phase 2 with 7 trials, with the heaviest enrollment activity in New York, Madison, and Baltimore. Lead sponsors running recurrent prostate cancer studies include British Columbia Cancer Agency, Columbia University, and Alpha Tau Medical LTD..

Browse recurrent prostate cancer trials by phase

Treatments under study

About Recurrent Prostate Cancer Clinical Trials

Looking for clinical trials for Recurrent Prostate Cancer? There are currently 11 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Recurrent Prostate Cancer trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Recurrent Prostate Cancer clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 115 of 15 trials

Recruiting
Phase 1Phase 2

Clinical Study to Assess the Safety and Efficacy of the SpectraCure P18 System

Recurrent Prostate Cancer
SpectraCure AB66 enrolled4 locationsNCT03067051
Recruiting
Phase 2

Stereotactic Body Radiation Therapy Plus Immediate or Delayed Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy or Salvage Radiation Therapy for the Treatment of Prostate Cancer, DIVINE Trial

Biochemically Recurrent Prostate CarcinomaRecurrent Castration-Sensitive Prostate CarcinomaRecurrent Prostate Cancer+1 more
Mayo Clinic532 enrolled3 locationsNCT06378866
Recruiting
Phase 2Phase 3

Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer

Prostate CancerMetastatic Prostate CancerOligometastasis+3 more
VA Office of Research and Development464 enrolled20 locationsNCT04787744
Recruiting
Phase 2

Terbinafine for Biochemically Recurrent Prostate Cancer (TerbinaPro)

Recurrent Prostate Cancer
Swiss Cancer Institute42 enrolled11 locationsNCT07365423
Recruiting
Phase 2

Enzalutamide and PDS01ADC in PET Positive Recurrent Prostate Cancer (pprPC) Without Testosterone Lowering Therapy

Prostate CancerRecurrent Prostate CancerPET Positive
National Cancer Institute (NCI)65 enrolled1 locationNCT06096870
Recruiting
Phase 1

Trial of pTVG-HP+Nivo+Targeted Ablation of Resistant Lesions in Non-Castrate RecurrentOMPC

Prostate Cancer PatientsRecurrent Prostate CancerOligometastatic Prostate Cancer (OMPC)+1 more
University of Wisconsin, Madison14 enrolled1 locationNCT07090148
Recruiting
Phase 2Phase 3

PSMA-PET Imaging for Detecting Early Metastatic Prostate Cancer in Men w/ High Decipher Test Scores

Prostate CancerRecurrent Prostate Cancer
H. Lee Moffitt Cancer Center and Research Institute60 enrolled1 locationNCT03495427
Recruiting
Not Applicable

Focal Radiotherapy for Previously Treated Prostate Cancer Patients

Locally Recurrent Prostate Cancer
Royal North Shore Hospital36 enrolled1 locationNCT03073278
Recruiting
Not Applicable

Partial Prostate Salvage High Dose Rate Brachytherapy

Recurrent Prostate Cancer
British Columbia Cancer Agency30 enrolled1 locationNCT03246802
Recruiting
Not Applicable

A Study to Assess Alpha DaRT224 for the Treatment of Men With Non-metastatic Locally Recurrent Prostate Cancer

Non-metastatic Prostate CancerLocally Recurrent Prostate Cancer
Alpha Tau Medical LTD.10 enrolled1 locationNCT06202248
Recruiting

Tumor Microenvironment Analysis of Prostate Cancer Metastasis

Recurrent Prostate Cancer
Columbia University16 enrolled1 locationNCT05304858
Recruiting
Phase 2

This Study is Evaluating a New Radiation Treatment Technique for Patients Who Have Had Prostate Cancer, Undergone Surgery for Cancer, and Then Have Evidence That Their Prostate Cancer Has Returned.

Recurrent Prostate Cancer After Surgery
University of Rochester80 enrolled1 locationNCT05946824
Recruiting
Not Applicable

Salvage Cryotherapy for Recurrent Prostate Cancer After Radiation Therapy

Prostate CancerRecurrent Prostate CancerCryotherapy
Ignacio Puche Sanz100 enrolled2 locationsNCT04891536
Recruiting

A pilot study evaluating focal irreversible electroporation as treatment for participants with recurrent prostate cancer after radiotherapy.

Recurrent Prostate Cancer
St. Vincent’s Private Hospital10 enrolled1 locationACTRN12617000806369
Recruiting
Phase 1

focal radiotherapy for previously treated prostate cancer patients

locally recurrent prostate cancer following definitive external beam radiotherapy
Northern Sydney Local Health District-Royal North Shore Hospital36 enrolled1 locationACTRN12617000035325